

2 MAY 2024 – Cytopeutics was honored by the visit of YB Tuan Chang Lih Kang, Minister of the Ministry of Science, Technology, and Innovation (MOSTI), alongside En. Khairul Fidzal Abdul Razak, CEO of the National Bioeconomy Corporation. The visit marked a significant milestone for Cytopeutics, which has previously benefited from MOSTI’s funding initiatives. On this momentous occasion, the Minister announced the award of the TED-2 grant to Cytopeutics, aimed at advancing their groundbreaking research in the field of cell and gene therapy.
The TED-2 grant will significantly advance Cytopeutics’ research efforts, particularly in the area of stroke treatment, offering immense potential to revolutionize therapeutic approaches in this emerging field. The Minister’s visit was further highlighted by the presentation of an award letter from the International Society for Cell and Gene Therapy (ISCT) to Prof. Dr. Chin, recognizing his significant contributions to the field. This honor marks Prof. Dr. Chin as the first Asian recipient of a global ISCT major award.
MOSTI has been the driving force in Malaysia in scientific innovations including medical biotech such as in the emerging field of cell and gene therapy. Cytopeutics has contributed significantly towards this national objective including nurturing local talent; and we are humbled to be acknowledged locally by MOSTI and globally by the international scientific community.
The TED-2 grant will significantly advance Cytopeutics’ research efforts, particularly in the area of stroke treatment, offering immense potential to revolutionize therapeutic approaches in this emerging field. The Minister’s visit was further highlighted by the presentation of an award letter from the International Society for Cell and Gene Therapy (ISCT) to Prof. Dr. Chin, recognizing his significant contributions to the field. This honor marks Prof. Dr. Chin as the first Asian recipient of a global ISCT major award.
MOSTI has been the driving force in Malaysia in scientific innovations including medical biotech such as in the emerging field of cell and gene therapy. Cytopeutics has contributed significantly towards this national objective including nurturing local talent; and we are humbled to be acknowledged locally by MOSTI and globally by the international scientific community.


During his speech, YB Tuan Chang Lih Kang commended Cytopeutics on their recent achievements:


“I would like to extend my heartfelt congratulations to Prof Chin and Cytopeutics for their achievements. It is glad that a local biotech company with local talents that is now globally recognised, including Prof Chin being the FIRST Asian to receive a major ISCT Global award in its 33 years of history.
Cytopeutics undertook extensive research and strict regulatory compliance to be the first to pass through NPRA Stage 2 screening for Cell and Gene Therapy Product registration.
I get to know that you have successfully completed the MOSTI Smartfund challenge with good results, and submitted for full product registration with MOH. And you worked very hard and allegiantly to be endorsed as Halal by IIFA under OIC. This is the first Halal stem cell in the world. Congratulations once again.”
Cytopeutics undertook extensive research and strict regulatory compliance to be the first to pass through NPRA Stage 2 screening for Cell and Gene Therapy Product registration.
I get to know that you have successfully completed the MOSTI Smartfund challenge with good results, and submitted for full product registration with MOH. And you worked very hard and allegiantly to be endorsed as Halal by IIFA under OIC. This is the first Halal stem cell in the world. Congratulations once again.”
The Minister expressed his enthusiasm for supporting local enterprises like Cytopeutics, noting, “We are very happy to support local enterprises like Cytopeutics. Recently, the ministry has just awarded the company another grant – the TED-2FUND Grant, which is a pre-commercialization fund to drive the development of stem cell treatment for stroke and other high-impact diseases.”
He concluded with words of encouragement for the future: “I hope Cytopeutics can continue to strive for many more excellent R&D, and to achieve more success in many years to come.”
He concluded with words of encouragement for the future: “I hope Cytopeutics can continue to strive for many more excellent R&D, and to achieve more success in many years to come.”
Cytopeutics is profoundly grateful for these double honors, which not only recognize their achievements locally by MOSTI but also on a global scale by the international scientific community. These acknowledgments motivate Cytopeutics to continue their pioneering work in cell and gene therapy, driving innovations that have the potential to transform medical treatments and improve lives.

